Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Veracyte, Inc. - Common Stock (NQ:VCYT)

42.40 -0.05 (-0.12%)
Streaming Delayed Price Updated: 11:12 AM EST, Jan 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Veracyte, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
New Data Presented at CHEST 2022 Reinforce Clinical Value of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Release Third Quarter 2022 Financial Results on November 2, 2022
From Veracyte, Inc.
Via Business Wire
News headline image
New Data Published in JNCI Demonstrate Veracyte’s Decipher Prostate Genomic Classifier May Improve Identification of Aggressive Prostate Cancer in African American Men
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Names John Leite, Ph.D., as General Manager of Pulmonology & Market Access
From Veracyte, Inc.
Via Business Wire
News headline image
New Data Presented at ESMO 2022 Show Veracyte’s Decipher Prostate Genomic Classifier May Help Inform Personalized Treatment Decisions in Men with Advanced Prostate Cancer
From Veracyte, Inc.
Via Business Wire
News headline image
New Data Suggest Veracyte’s Envisia Genomic Classifier Can Help Predict Disease Progression in Interstitial Lung Disease Patients Treated with Combination Immunosuppressive Therapy
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces Seven Abstracts to Be Presented at ESMO Congress 2022
From Veracyte, Inc.
Via Business Wire
News headline image
New Data in Nature Medicine Suggest Pre-Treatment Tumor Microenvironment Can Impact Response for CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma
From Veracyte, Inc.
Via Business Wire
News headline image
Whither Small Caps After Fed’s Tough Talk? ↗
For now its better not to “Fight the Fed” because they are fighting the with the market. Now that everyone is scared of the Fed's rhetoric it would be better to wait a week or so as more data and... 
Via Talk Markets
News headline image
Veracyte Appoints Eliav Barr, M.D., to Its Board of Directors
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte: Q2 Earnings Insights ↗
Veracyte (NASDAQ:VCYT) reported its Q2 earnings results on Tuesday, August 2, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Veracyte beat estimated earnings by... 
Via Benzinga
News headline image
Veracyte Announces Second Quarter 2022 Financial Results
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte's Earnings: A Preview ↗
Veracyte (NASDAQ:VCYT) is set to give its latest quarterly earnings report on Tuesday, 2022-08-02. Here's what investors need to know before the announcement. Analysts estimate that Veracyte will... 
Via Benzinga
News headline image
Earnings Scheduled For August 2, 2022 ↗
Companies Reporting Before The Bell • Ferrari (NYSE:RACE) is expected to report quarterly earnings at $1.27 per share on revenue of $1.22 billion. 
Via Benzinga
News headline image
Veracyte Announces New Clinical Validation Data for RNA Sequencing-Based Afirma Medullary Thyroid Cancer Classifier Published in Thyroid
From Veracyte, Inc.
Via Business Wire
News headline image
Small Cap Biotech Stocks Are Trending Well ↗
Despite a little weakness last week, small cap biotechs are trending well for traders. For investors entering the trade on July 5 all of our. focus stocks are up except ChemoCentryx. 
Via Talk Markets
News headline image
Veracyte to Release Second Quarter 2022 Financial Results on August 2, 2022
From Veracyte, Inc.
Via Business Wire
News headline image
New Data Published in PLOS ONE Validate the Clinical Performance of Veracyte’s Percepta Genomic Sequencing Classifier in Lung Cancer Diagnosis
From Veracyte, Inc.
Via Business Wire
News headline image
Small Cap Biotechs Regain Momentum ↗
Smaller cap biotech stocks soared off from recent lows looking like a redux of early 2021 when prices were double that of current values. 
Via Talk Markets
News headline image
Veracyte Named a San Francisco “Bay Area Top Workplace” For Ninth Consecutive Year
From Veracyte, Inc.
Via Business Wire
News headline image
Bear Market Rally Lifts HealthCare Stocks Off Bottom ↗
Clearly we are in a biotech bear market with both diagnostics and vaccine revenues stalled. If gene editing stocks cannot offer breakthrough clinical news then stick with large cap biopharma. 
Via Talk Markets
News headline image
New Data Show Strong Performance of Veracyte’s Afirma GSC in Real-World Clinical Practice
From Veracyte, Inc.
Via Business Wire
News headline image
Data Published in Annals of Oncology Reinforce Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier for Informing Treatment of Men Experiencing Prostate Cancer Progression
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces that New Data Show Immunoscore IC Assay May Predict Patients Likely to Benefit from Addition of Immunotherapy to Standard First-Line Therapy for Metastatic Colorectal Cancer
From Veracyte, Inc.
Via Business Wire
News headline image
New Data to be Shared at ASCO 2022 Underscore Clinical Utility of Decipher Prostate Genomic Classifier
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces New Data to be Presented at ASCO 2022 Showing Immunoscore IC Assay’s Ability to Identify Patients with NSCLC Who May Benefit from Immune Checkpoint Inhibitors
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Present at Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces New Data Reinforcing Percepta Nasal Swab Test’s Clinical Performance and Utility in Lung Cancer Risk Assessment
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Earnings Perspective: Return On Capital Employed ↗
Veracyte (NASDAQ:VCYT) brought in sales totaling $67.78 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 37.36%, resulting in a loss of $14.46 million. 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.